Welcome to our dedicated page for Natera SEC filings (Ticker: NTRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Natera’s genomic jargon isn’t easy. Each 10-K details everything from cfDNA assay accuracy to payer reimbursement disputes, while 8-K updates often cover fast-moving clinical-trial milestones. If you’ve ever wondered how to locate test-volume data, or needed Natera insider trading Form 4 transactions before the market reacts, you know the challenge.
Stock Titan solves it. Our AI reads every Natera quarterly earnings report 10-Q filing, highlights revenue per test, and translates accounting footnotes into plain language. Real-time alerts flag Natera Form 4 insider transactions real-time, so you can track executive stock moves the moment they hit EDGAR. Need the full picture? We link each 10-K, 10-Q, 8-K, proxy DEF 14A, and S-8 in one place—Natera SEC filings explained simply. Common questions such as “How do I find the latest Natera proxy statement executive compensation?” or “Where is the Natera 8-K material events explained?” are answered inside every filing card.
Our platform doesn’t stop at document delivery. AI-powered summaries spotlight what matters for a diagnostics company: R&D spend versus cash on hand, progress of the Signatera oncology pipeline, and changes in CMS reimbursement that can swing margins. Use cases include:
- Compare quarter-over-quarter test volumes without sifting through tables
- Monitor Natera executive stock transactions Form 4 for buying or selling trends
- Assess dilution risk by reviewing shelf registrations and ATM offerings
- Download an Natera annual report 10-K simplified PDF automatically annotated by AI
- Receive instant alerts when a new Natera earnings report filing analysis is available
- Get guidance on understanding Natera SEC documents with AI-generated glossaries
Whether you’re a healthcare analyst, portfolio manager, or clinician-investor, Stock Titan turns Natera’s dense disclosures into actionable insight—no genetics PhD required.
Natera (NTRA)149 Restricted Stock Units (RSUs) issued in lieu of a $26,875 quarterly board retainer, and the RSUs were fully vested at grant.
After this transaction, the reporting person beneficially owned 6,839 shares directly and 1,224,787 shares indirectly through estate planning vehicles.
Natera, Inc. (NTRA) reported a routine insider transaction. A director filed a Form 4 showing an award of 93 Restricted Stock Units (RSUs) on 10/31/2025 in lieu of quarterly retainer fees of $16,875 for board service. The filing states the RSUs were fully vested at issuance, and each RSU represents the right to receive one share of common stock. Following this transaction, the reporting person beneficially owned 5,221 shares, held directly.
Natera, Inc. (NTRA) reported an insider equity award. On 10/31/2025, a director received 93 restricted stock units (RSUs) in lieu of a quarterly board retainer of $16,875. The filing states these RSUs were fully vested at issuance, and each RSU represents the right to receive one share of Natera common stock.
Following this transaction, the reporting person beneficially owned 18,359 shares, held directly.
Natera (NTRA) CEO and President reported multiple insider transactions on 11/03/2025. He exercised stock options for 2,084 shares at $13.01, 3,595 shares at $20.27, and 150,000 shares at $119.75, then sold 2,215 shares at a weighted average of $198.0293, 1,915 shares at $198.9619, and 156,573 shares at $199.9983. Following these trades, he beneficially owned 144,816 shares directly. The sales were made under a Rule 10b5-1 plan adopted on December 11, 2023 and amended on December 2, 2024.
Natera (NTRA) reported an insider transaction on a Form 4. On 11/03/2025, the Executive Chairman, who is also a Director, sold 17,100 shares of common stock at a $200.0002 weighted average price, executed under a Rule 10b5-1 trading plan adopted on June 13, 2025. Following the sale, the reporting person beneficially owns 2,303,752 shares directly and 5,000 shares indirectly through a spouse. The sale price reflects multiple trades between $200.00 and $200.01 per share.
Natera (NTRA) CEO and President, who also serves as a Director, reported two sales of common stock. On 10/27/2025, he sold 2,335 shares at $192.324, and on 10/28/2025, he sold 3,680 shares at $191.4619. Following these transactions, he beneficially owned 149,840 shares.
The filing states both sales were executed to satisfy tax withholding obligations tied to RSU vesting and were made pursuant to a written instruction intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Natera, Inc. (NTRA): CFO reported open‑market sales on Form 4. The Chief Financial Officer executed multiple sales of common stock on 10/27/2025, 10/28/2025, and 10/29/2025. Reported transactions include 781 shares at $192.324 on 10/27, 1,237 shares on 10/28 at a weighted average price, and additional sales on 10/28 and 10/29 at weighted average prices within stated ranges. Following the reported transactions, the officer directly owned 64,126 shares.
Footnotes state that the 10/27 sale and the first 10/28 sale were effected to satisfy tax withholding and remittance obligations upon RSU vesting, pursuant to a written instruction intended to satisfy Rule 10b5‑1(c). The remaining sales were effected under a Rule 10b5‑1 trading plan adopted on June 14, 2024. Several prices are reported as weighted averages with detailed per‑trade ranges available upon request.
Natera, Inc. (NTRA) reported insider activity as a director and co‑founder filed a Form 4 disclosing small open‑market sales tied to RSU tax withholding. On 10/27/2025, the reporting person sold 288 shares at $192.324. On 10/28/2025, they sold 191 shares at $191.4619. Following these transactions, the filer reported 235,921 shares held directly. The filing also lists indirect holdings of 28,032 shares each by Caraluna 1 Trust and Caraluna 2 Trust. The sales were executed under a Rule 10b5‑1(c) written instruction connected to RSU vesting.
Natera (NTRA) reported an insider transaction by its SEC and Chief Legal Officer. The officer sold 935 shares of common stock on 10/27/2025 at $192.324 and 1,058 shares on 10/28/2025 at $191.4619. Both sales were made to satisfy tax withholding obligations related to RSU vesting and were executed under a written instruction intended to satisfy Rule 10b5-1(c).
Following these transactions, the officer beneficially owned 201,699 shares directly.
Natera (NTRA) reported insider transactions by its President, Clinical Diagnostics. The reporting person sold 1,008 shares of common stock at $192.324 on 10/27/2025 and 1,198 shares at $191.4619 on 10/28/2025. These sales were made to satisfy tax withholding and remittance obligations related to RSU vesting and were executed pursuant to a written instruction intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Following the transactions, beneficial ownership was 116,259 shares after the first sale and 115,061 shares after the second sale, held directly.
FAQ
What is the current stock price of Natera (NTRA)?
What is the market cap of Natera (NTRA)?
